King Wealth Management Group Lowers stake in Concert Pharmaceuticals Inc (CNCE)

Concert Pharmaceuticals Inc (CNCE) : King Wealth Management Group reduced its stake in Concert Pharmaceuticals Inc by 1.54% during the most recent quarter end. The investment management company now holds a total of 30,882 shares of Concert Pharmaceuticals Inc which is valued at $339,393 after selling 484 shares in Concert Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Concert Pharmaceuticals Inc makes up approximately 0.17% of King Wealth Management Group’s portfolio.

Other Hedge Funds, Including , Senzar Asset Management reduced its stake in CNCE by selling 670,905 shares or 45.59% in the most recent quarter. The Hedge Fund company now holds 800,788 shares of CNCE which is valued at $8,800,660. Concert Pharmaceuticals Inc makes up approx 1.75% of Senzar Asset Management’s portfolio.Rhumbline Advisers boosted its stake in CNCE in the latest quarter, The investment management firm added 2,414 additional shares and now holds a total of 17,248 shares of Concert Pharmaceuticals Inc which is valued at $189,556.Ramsey Quantitative Systems boosted its stake in CNCE in the latest quarter, The investment management firm added 38,102 additional shares and now holds a total of 73,383 shares of Concert Pharmaceuticals Inc which is valued at $806,479. Concert Pharmaceuticals Inc makes up approx 0.85% of Ramsey Quantitative Systems’s portfolio.Blackrock Group Ltd reduced its stake in CNCE by selling 84 shares or 2.38% in the most recent quarter. The Hedge Fund company now holds 3,447 shares of CNCE which is valued at $37,883.Mufg Americas Holdings Corp boosted its stake in CNCE in the latest quarter, The investment management firm added 2,077 additional shares and now holds a total of 2,287 shares of Concert Pharmaceuticals Inc which is valued at $25,180.

Concert Pharmaceuticals Inc closed down -0.48 points or -4.73% at $9.66 with 1,11,061 shares getting traded on Monday. Post opening the session at $10.13, the shares hit an intraday low of $9.64 and an intraday high of $10.33 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on Concert Pharmaceuticals Inc. Stifel Initiated Concert Pharmaceuticals Inc on Jul 1, 2016 to “Buy”, Price Target of the shares are set at $23.

Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimer’s agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *